Development and Utility of a PAK1-Selective Degrader

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Overexpression of PAK1 (p21-activated kinase 1) is prevalent in various cancers, making it a potential therapeutic target.
• Existing PAK1 inhibitors face challenges due to the essential role of PAK2 in cardiovascular function.
• NVS-PAK1-1, a selective PAK1 inhibitor, shows modest potency.

Purpose of the Study:

• To develop a novel therapeutic strategy for PAK1-dependent cancers.
• To investigate the efficacy of selective PAK1 degradation over catalytic inhibition.
• To create a more potent and selective PAK1-targeting agent.

Main Methods:

• Development of BJG-05-039, a novel PAK1 degrader by conjugating NVS-PAK1-1 with lenalidomide.
• Assessment of BJG-05-039's ability to selectively degrade PAK1 in cancer cell lines.
• Evaluation of the anti-proliferative effects of BJG-05-039 in PAK1-dependent and PAK2-dependent cell lines.

Main Results:

• BJG-05-039 successfully induced selective degradation of PAK1.
• BJG-05-039 demonstrated enhanced anti-proliferative activity compared to its parent compound in PAK1-dependent cell lines.
• No significant effects were observed in PAK2-dependent cell lines, indicating selectivity.

Conclusions:

• Selective degradation of PAK1 is a potent therapeutic strategy for PAK1-dependent malignancies.
• PAK1 degradation offers potential advantages over traditional catalytic inhibition.
• BJG-05-039 represents a promising candidate for further development in cancer therapy.